Considering that EPCAM deletions have a relatively high frequency in MMR-d tumors (21.4% in MMR-d metastatic tumors), we presume that the prevalence of Lynch syndrome in MMR-d prostate cancer may be higher than previously thought [33]. This evidence concerns the gene EPCAM and Lynch syndrome.